Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Auteurs : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 895-902

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Jaar : 2018
Journal : Ann Oncol
Volume : 29(8)
Pagina's : 1777-1783

Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Powles RL, Redmond D, Sotiriou C, Loi S, Fumagalli D, Nuciforo P, Harbeck N, de Azambuja E, Sarp S, Di Cosimo S, Huober J, Baselga J, Piccart-Gebhart M, Elemento O, Pusztai L, Hatzis C
Jaar : 2018
Journal : JAMA Oncol
Volume : 4
Pagina's : e181564

Neoadjuvant treatment: the future of patients with breast cancer.

Auteurs : Reyal F, Hamy AS, Piccart-Gebhart M
Jaar : 2018
Journal : ESMO Open
Volume : 3
Pagina's : e000371

Treatment of advanced HER2-positive breast cancer: 2018 and beyond.

Auteurs : Pondé N, Brandão M, El-Hachem G, Werbrouck E, Piccart-Gebhart M
Jaar : 2018
Journal : Cancer Treat Rev
Volume : 67
Pagina's : 10-20

Potential Benefit of Intra-operative Administration of Ketorolac on Breast Cancer Recurrence According to the Patient's Body Mass Index.

Auteurs : Desmedt C, Demicheli R, Fornili M, Bachir I, Duca M, Viglietti G, Berlière M, Piccart-Gebhart M, Sotiriou C, Sosnowski M, Forget P, Biganzoli E
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(10)
Pagina's : 1115-1122

PUBLISHED ERRATUM (2016): PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Auteurs : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Jaar : 2018
Journal : Ann Oncol
Volume : 29
Pagina's : 2151

erratum :Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Jaar : 2018
Journal : Ann Oncol
Volume : 29
Pagina's : 2152

Reply to ESMO-MCBS v1.1: Statistical and Patient Relevant Shortcomings" by R. Emprechtinger et al."

Auteurs : Cherny NI, Dafni U, Piccart-Gebhart M, Latino NJ, Douillard JY, Bogaerts J, Karlis D, Zygoura P, Pentheroudakis G, Tabernero J, Zielinski C, de Vries EGE
Jaar : 2018
Journal : Ann Oncol
Volume : 29(5)
Pagina's : 1335-1338

Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).

Auteurs : Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, Fumagalli D, Bozovic-Spasojevic I, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im YH, Borrego MR, Chen DR, Rodeheffer R, Piccart-Gebhart M, Suter T, de Azambuja E
Jaar : 2018
Journal : Breast Cancer Res Treat
Volume : 168(3)
Pagina's : 631-638

The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.

Auteurs : Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart M, Baselga J, de Azambuja E
Jaar : 2018
Journal : Eur J Cancer
Volume : 89
Pagina's : 42-48

Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.

Auteurs : Buisseret L, Pommey S, Allard B, Garaud S, Bergeron M, Cousineau I, Ameye L, Bareche Y, Paesmans M, Crown JPA, Di Leo A, Loi S, Piccart-Gebhart M, Willard-Gallo K, Sotiriou C, Stagg J
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 1056-62

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.

Auteurs : Sonnenblick A, Salgado R, Brohée S, Zahavi T, Peretz T, Van den Eynden G, Rouas G, Salmon A, Francis PA, Di Leo A, Crown JPA, Viale G, Daly L, Javdan B, Fujisawa S, de Azambuja E, Ameye L, Piccart-Gebhart M, Bromberg JF, Sotiriou C
Jaar : 2018
Journal : Int J Oncol
Volume : 52(2)
Pagina's : 424-432

Reply to The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al."

Auteurs : Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B
Jaar : 2018
Journal : Ann Oncol
Volume : 29(1)
Pagina's : 281-282

Charcot-Marie-Tooth hereditary neuropathy revealed after administration of docetaxel in advanced breast cancer.

Auteurs : Kourie HR, Mavroudakis N, Aftimos P, Piccart-Gebhart M
Jaar : 2017
Journal : World J Clin Oncol
Volume : 8
Pagina's : 425-428

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Auteurs : Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EGE, Piccart-Gebhart M
Jaar : 2017
Journal : Ann Oncol
Volume : 28
Pagina's : 2901-2905

Adenoid cystic carcinoma of the breast - an aggressive presentation with pulmonary, kidney, and brain metastases: a case report.

Auteurs : Mhamdi HA, Kourie HR, Jungels C, Aftimos P, Belbaraka R, Piccart-Gebhart M
Jaar : 2017
Journal : J Med Case Rep
Volume : 11
Pagina's : 303

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.

Auteurs : Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart-Gebhart M, de Vries EGE, Latino NJ, Douillard JY, Cherny NI
Jaar : 2017
Journal : ESMO Open
Volume : 2
Pagina's : e000216

Recurrence dynamics of breast cancer according to baseline body mass index.

Auteurs : Biganzoli E, Desmedt C, Fornili M, de Azambuja E, Cornez N, Ries F, Closon-Dejardin MT, Kerger J, Focan C, Di Leo A, Nogaret JM, Sotiriou C, Piccart-Gebhart M, Demicheli R
Jaar : 2017
Journal : Eur J Cancer
Volume : 87
Pagina's : 10-20

Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE).

Auteurs : Loibl S, de la Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, Bermejo B, Untch M, Lee SC, Turri S, Urban P, Kümmel S, Steger G, Gombos A, Lux M, Piccart-Gebhart M, Von Minckwitz G, Baselga J, Loi S
Jaar : 2017
Journal : Eur J Cancer
Volume : 85
Pagina's : 133-145